The influence of spleen aminopeptidase lyophilized powder on serum levels of TGF-β1, MCP-1, SDF-1 in pediatric asthma

Abstract

Objective To investigate the influence of spleen aminopeptidase lyophilized powder on serum levels of transforming growth factor-β1 (TGF-β1), monocyte chemoattractant protein-1 (MCP-1), stromal cell derived factor 1(SDF-1) in pediatric asthma. Methods 128 patients with asthma were randomly divided into observation group(64 cases) and control group (64 cases). Two groups of children were given symptomatic treatment.The control group was orally administered montelukast, the observation group was treated with montelukast and splenic ammonia lyophilized powder for 3 months.The levels of TGF-β1, MCP-1, SDF-1 of the two groups were compared before and after treatment. Results After treatment, the asthma control test table (ACT) score, expiratory volume in one second (FEV1) and peak expiratory flow rate (PEF) in the observation group were (24.25±3.98)points (80.25±4.25)%, (7.25±0.69)L/min, which were significantly higher than those in the control group [(20.12±4.02)points, (75.02±3.96)%, (5.82±0.70)L/min, t=7.203, 6.757, 14.459, 26.677, P<0.01]. After treatment, the serum levels of TGF-β1, MCP-1, SDF-1 of the observation group were (42.23±6.02)ng/mL, (48.56±3.96)pg/mL, (252.36±32.22)ng/L, which were significantly lower than those in the control group [(42.23±6.02)ng/mL, (59.02±4.22)pg/mL, (425.25±40.62)ng/L, t=6.757, 14.459, 26.677, all P<0.01]. Conclusion Montelukast combined with splenic aminopeptidase lyophilized powder for asthma can effectively reduce serum TGF-β1, MCP-1, SDF-1 levels and improve clinical symptoms and lung function, improve the treatment of children. Key words: Asthma; Montelukast; Spleen aminopeptidase oral lyophilized powder; Transforming growth factor-β1; Monocyte chemoattractant protein-1; Stromal cell derived factor-1